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Glioblastoma multiforme is a heterogeneous and
infiltrative cancer with dismal prognosis. Studying
the migratory behavior of tumor-derived cell popula-
tions can be informative, but it places a high premium
on the precision of in vitromethods and the relevance
of in vivo conditions. In particular, the analysis of 2D
cell migration may not reflect invasion into 3D extra-
cellular matrices in vivo. Here, we describe a method
that allows time-resolved studies of primary cell
migration with single-cell resolution on a fibrillar sur-
face that closely mimics in vivo 3D migration. We
used this platform to screen 14 patient-derived glio-
blastoma samples. We observed that the migratory
phenotype of a subset of cells in response to
platelet-derived growth factor was highly predictive
of tumor location and recurrence in the clinic. There-
fore, migratory phenotypic classifiers analyzed at the
single-cell level in a patient-specific way can provide
high diagnostic and prognostic value for invasive
cancers.INTRODUCTION
Aggressive cancers, such as glioblastomamultiforme (GBM), are
of particular interest due to the heterogeneous nature of individ-
ual tumors (Snuderl et al., 2011; Szerlip et al., 2012) and high
recurrence following surgical resection (Filippini et al., 2008;
McGirt et al., 2009; Chaichana et al., 2013, 2014). Genomic
and proteomic profiling can provide a wealth of information
about tumor samples, including cancer-specific mutations and
clinically relevant subclasses (Verhaak et al., 2010). However,
these cell population-based analyses ignore the diversity of indi-
vidual cells that can predetermine the aggressiveness of a given
tumor. High-throughput genomic and proteomic single-cell ana-2616 Cell Reports 15, 2616–2624, June 21, 2016 ª 2016 The Author(
This is an open access article under the CC BY-NC-ND license (http://lyses of multiple samples are not within reach of clinical applica-
tions (Kalisky et al., 2011; Meier et al., 2013). Furthermore,
aggressive cell migration can be a product of multiple and
distinct combinations of genetic alterations and would benefit
from a complementary analysis of phenotypic properties at the
individual cell level. As with many other cancers, individual
GBM cells can spread from the primary tumor bulk, avoid detec-
tion, and form secondary tumor foci (Sahai, 2007). Growth fac-
tors, e.g., platelet-derived growth factor (PDGF), have emerged
as enhancers of malignant potential in GBM, because they affect
cell migration and proliferation (Fomchenko and Holland, 2007;
Shih andHolland, 2006). Various components of the extracellular
matrix (ECM), such as laminin, have also been implicated inmod-
ulation of cell migration (Friedl andWolf, 2010; Petrie et al., 2009;
Wirtz et al., 2011; Anton et al., 1999; Porcionatto, 2006). Direc-
tional cell migration can be guided by a variety of mechanical
cues presented by ECM structures ranging in size from nanome-
ters to microns (Kim et al., 2009a, 2012; Park et al., 2016). There-
fore, a challenge is to develop an experimental platform that will
model the mechano-chemical cellular milieu yet remain simple
and accessible to allow practical, high-throughput use. In this
study, we demonstrate that single-cell-resolution phenotypic
screening holds great promise in prognostic analysis of glioblas-
toma samples. We found that the clinical outcome of GBM tu-
mors strongly correlated with the response to two environmental
inputs: the nanotopography and the growth factor PDGF. The
ability to observe this responsiveness at the single-cell level
and thus examine different cell subpopulations was critical for
the success of this phenotypic analysis, revealing correlations
with such critical prognostic tumor characteristics as time of
recurrence after resection.
RESULTS
Construction and Application of a Phenotypic-
Screening Platform
To create 1D fibrillar surfaces that mimic nanometer-scale
features of the 3D ECM microenvironment, we fabricateds).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. Phenotypic Screening of Heterogeneous Cell Populations Recapitulates the Microenvironment of Migrating Cells
(A) Cells with heterogeneous phenotypes are isolated from a patient’s tumor (MRI of tumor for sample GBM 612).
(B) The cells are seeded on a platform that has amulti-well structure, allowing testing ofmultiple conditions, and is an on-glass technology, allowing direct imaging
of migration and morphology with single-cell resolution.
(C) Images show that GBM 612 cells migrating on the platform have similar morphology and migration speed compared to GBM 612 cells migrating in ex vivo
human brain tissue and 3D Matrigel. In comparison, cells migrating on flat surfaces are not polarized and have reduced migration speeds compared to the other
cases (see Supplemental Information) (scale bars, 25 mm; duration between each frame, 1 hr).
(D) ROCK inhibitor (Y-27632) affects migration of GBM 612 cells on tissue-mimetic substrates and flat surfaces (n = 30 cells, mean + SEM, ***p < 0.0001, *paired
against control group, #paired against 3 mM group, Kruskal-Wallis one-way ANOVA on ranks, Dunn’s method).
(E) The platform provides important information on the migration response of heterogeneous cell populations. GBM 612 samples show a subpopulation of cells
whose migration is fast and stable over time.topographic patterns consisting of regular, parallel ridges (Fig-
ures 1A, 1B, and S1A–S1C) similar in size to those found in the
brain tissue ECM (Kim et al., 2009b; Bellail et al., 2004; Ottani
et al., 2001). We explored how well cell migration on the quasi-
3D, fibrillar topography approximated cell migration in a true
3D ECM environment. We compared the morphology, direction-
ality, and speed of GBM 612 cells on our platform and cells
migrating in distinct 3D settings: Matrigel matrix and organotypic
human brain slice cultures (Figure 1C). We found that cell
morphology on fibrillar, but not flat, surfaces mirrored the char-
acteristic cell shapes found in 3D environments. Cell morphology
in collagen 3Dmatrices was similar to that observed in our tissue
mimetic platform (Huang et al., 2016). Furthermore, in contrast to
2D surfaces, migration speed was enhanced to levels similar to
those observed in 3D settings (Figure 1C), displaying essentially
1D migration patterns. We replicated the same observations us-ing other patient-derived cell lines (GBM 318 and GBM 276) (Fig-
ures S1B, S1D, and S1J). Consistent with a tendency of mobile
cells to align parallel to oriented topographic structures (Friedl
and Wolf, 2010), the direction of cell migration was strongly
biased along the axis of the ridge pattern (Figures S1D and
S1J; Movies S1, S2, and S3). Compared to smooth surfaces,
cells cultured on the platform showed increased cell area and
spindle shape factor (Figures S1E, S1H, and S1I), and their
migration was enhanced based on the three metrics scored:
average speed, alignment, and persistence (Figures S1F, S1G,
S1K, and S1L). These results suggested a high degree of similar-
ity between our platform and the true 3D microenvironments,
possibly due to similar molecular mechanisms observed in cells
migrating on 1D fibrillar surfaces and 3D matrices but distinct
from those observed in cells cultured on 2D surfaces (Doyle
et al., 2009). To test the similarity between 1D fibrillar surfacesCell Reports 15, 2616–2624, June 21, 2016 2617
and 3D microenvironments, we analyzed the effect of the Rho-
associated protein kinase (ROCK) inhibitor Y-27632 on the
migration of GBM 612 cells (Figure 1D). We found that
Y-27632 inhibited migration on fibrillar surfaces but not on flat
surfaces, suggesting that myosin II plays a role in migration on
the fibrillar surfaces, similar to findings in vivo (Beadle et al.,
2008). We replicated these experiments with GBM 965 (Figures
S1M and S1N). Using the multi-well setup of the device, we
then explored the influence of two critical environmental cues:
ECM density and growth factor (Figure S2). On the fibrillar sur-
faces, but not on the flat surfaces, we observed a strong depen-
dence of cell velocity values on the surface density of laminin
(Figures S2A, S2B, S2E, and S2F). The density at which cell
migration speed was maximized was used in all subsequent ex-
periments. Next, we examined the distributions of cell velocities.
We found that cell migration was highly heterogeneous, display-
ing a substantial number of outliers, some exceeding the
average cell migration 3- to 4-fold (Figure 1E). Our results
confirm that the heterogeneity of cell behavior can be assessed
in this platform, enabling the identification and characterization
of rare cells with extreme properties.
Migratory Behavior of GBM Cells Can Be Altered in
Response to a Combination of PDGF and
Nanotopographic Cues
We explored whether 3D-like cell migration might be differen-
tially sensitive to the effects of growth factors implicated in the
onset and progression of glioma, e.g., PDGF-AA (PDGF).
PDGF can control glioma cell proliferation, but its effect on
GBMmigration and invasion is less clear (Feng et al., 2012; Lau-
rent et al., 2003). We tested the effects of PDGF on cell speed
and persistence at different doses. On our platform, we found
a dose-dependent response, with maximal motility achieved at
intermediate PDGF concentrations (Figure S2D, S2G, and
S2H). Similar experiments on flat substrata showed more limited
response to PDGF (Figure S2C). We then explored whether the
effect of PDGF could be ascribed to the activation of PDGF re-
ceptor alpha (PDGFRa). PDGFRa is thought to be the exclusive
receptor for the PDGF-AA isoform employed in this study (Fom-
chenko and Holland, 2007). First, we examined the expression
levels of PDGFRa in patient-derived cell lines by RT-PCR
and immunoblotting (Figure 2A, 2B, and S3A–S3C). Then, we
analyzed the migratory behavior of cells with low and high
PDGFRa expression levels (GBM 253 and GBM 276, respec-
tively). Following exposure to PDGF, we found an increase in
cell speed and directionality of GBM 276 cells (high PDGFRa
expression) but no response in GBM 253 (low PDGFRa expres-
sion) (Figures 2C–2G). To further ascertain that PDGFRa was
functionally involved, we used the tyrosine kinase inhibitor imati-
nib and found that migration was attenuated to similar levels in
both cell lines (Figures 2C, 2D, S3D, and S3E). However, a
detailed analysis of the GBM 276 subpopulations showed a
highly heterogeneous single-cell response to PDGF. In partic-
ular, only the fastest 25% quartile of cells responded to PDGF,
with the response abrogated by the inhibitor (Figures 2F
and 2G). Furthermore, the response of the slowest 25% quartile
of GBM 276 cells was analogous to that of the PDGF-unrespon-
sive cell line GBM253 (Figures 2E and 2F). These results suggest2618 Cell Reports 15, 2616–2624, June 21, 2016that migration of only a subset of cells is responsive to PDGF
stimulation and that this subset represents the fastest cell
subpopulation.
PDGF Enhances Invasiveness of Patient-Derived Cells
In Vivo
Using orthotopic human GBM tumor models in mice (Figures
S3F–S3J) (Garzon-Muvdi et al., 2012; Gonzalez-Perez et al.,
2010), we explored the role of PDGF in tumor growth and sur-
vival. First, we examined the behavior of the xenografts using
GBM 276 cells, cultured in the presence or absence of PDGF
for 3 weeks before injection. This PDGF preculture selects for
PDGF-responsive cells by stimulating their growth and enriching
this cell subpopulation. In vitro analysis of GBM 276 cells
showed that increased proliferation correlated with the PDGF-
induced migratory response (Figures S3M–S3R). We observed
significantly reduced survival of mice injected with PDGF-pre-
conditioned cells (n = 4 each group) (Figure 2H). Although this
result suggested the importance of highly PDGF-responsive
cells for tumor aggressiveness, we could exclude other effects
of prolonged PDGF exposure, e.g., transdifferentiation (Fig-
ure S3Q). We thus tested the putative role of PDGF in tumor
spreading by supplying this factor exogenously in vivo to existing
tumor xenografts via infusion pump (Figure S3F). Quantification
of tumor size and qualitative analysis by a blinded neuropathol-
ogist suggested that continuous exposure of tumor xenografts to
PDGF generated larger, more invasive tumors with more eccen-
tric shapes (Figure S3K). These samples displayed features
indicative of migration along fiber tracts. We also observed
increased dispersion of GBM cells beyond the tumor margins
(Figure S3L). These findings confirm the role of this growth factor
in tumor induction and progression that was observed in other
animal models (Fomchenko and Holland, 2007; Jackson et al.,
2006; Lokker et al., 2002), and they are consistent with clinical
data from The Cancer GenomeAtlas (TCGA) (Goswami and Nak-
shatri, 2013) suggesting significant correlation between PDGF
expression and survival (Figure 2I). TCGA data did not show a
similar correlation for PDGFRa expression (Figure 2J). Because
the genomic data did not support the correlation between
average PDGFR expression and patient outcomes, we exam-
ined the correlation between the tumor characteristics and the
cell migration data obtained in the tissue-mimetic platform.
Screening Heterogeneity within and between Patient-
Specific Tumor Samples
Heterogeneity of cell properties within the same tumor reflects
subpopulations promoting tumor growth, progression, and ther-
apeutic resistance (Snuderl et al., 2011). GBM is also known to
have populations with distinct expression profiles of receptor
tyrosine kinases, particularly PDGFRa (Snuderl et al., 2011;
Szerlip et al., 2012). This heterogeneity requires analysis on the
single-cell level, which is yielded in our platform with less than
1,000 cells (particularly beneficial for screening precious intrao-
perative human tissue specimens). We took advantage of the
single-cell resolution to quantify the distribution of cell speed in
control versus PDGF-exposed conditions and investigate the
difference in migratory behaviors among 14 glioblastoma pa-
tients (Figures 3A–3C). We found both intra- and inter-patient
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Figure 2. Migratory Response to PDGF Corre-
lates with Tumor Characteristics Both In Vitro
and In Vivo
(A) RT-PCR analysis of PDGFRa mRNA levels in re-
sponding sample GBM 276 and non-responding sam-
ple GBM 253 (n = 3, *p = 0.006, Student’s t test).
(B) Western blot for PDGFRa protein expression in GBM
samples grown as adherent or spheroid cultures.
(C and D) Quantification of migration speed of cell lines
GBM253 (C) and GBM276 (D) in the presence of PDGF-
AA (50 ng/ml) and imatinib (30 mM) (nz 80 cells, mean +
SEM, *p < 0.05, **p < 0.01, ***p < 0.001, *paired against
control group, #paired against PDGF group, Kruskal-
Wallis one-way ANOVA on ranks, Dunn’s method) (as-
terisks indicate pairing against the control group, hash
marks indicated pairing against the PDGF group).
(E and F) Migration speed of GBM 276 for the slowest
(E) and fastest (F) quartile of the cells (i.e., 25% of
the slowest- and fastest-moving cells, respectively),
showing that only a subpopulation responds to PDGF.
(G) Quantification of migration measured by alignment
of GBM 276 cells (*p < 0.05, Kruskal-Wallis one-way
ANOVA on ranks, Dunn’s method) (asterisks indicate
comparisons to all other conditions).
(H) Survival curves of mice injected with GBM 276 cells
cultured in control spheroid conditions or in the pres-
ence of PDGF-AA (n = 4 mice per group, *p = 0.0097,
Gehan-Breslow-Wilcoxon test).
(I and J) Kaplan-Meier plots based on clinical TCGA
data of GBM patients, comparing survival between high
and low expression of PDGF-AA (I) and PDGFRa (J),
respectively. The cohorts were divided at the median of
the expression level of the respective gene.differences in the cell population behavior. When analyzing GBM
499 cells based on their speed, the total population average
showed no significant response to PDGF, while analysis of the
25% fastest quartile subpopulation revealed significant differ-Cences (Figure 3A). Such masked responses
and heterogeneities were also present in the
time-domain data. For instance, two patient
samples, GBM 501 and GBM 609, responded
significantly to PDGF. However, for GBM 501,
this response was not persistent throughout
the experiment duration, in contrast to the
response of GBM 609 (Figure 3B). Finally,
the platform allowed us to investigate high-
speed outliers. For example, for both the
GBM 630 and the GBM 544 samples, cells
experienced a significant increase in migra-
tion speed in response to PDGF. However, a
detailed analysis of the speed distribution
revealed that only for GBM 630 were fast-
moving outliers clearly identifiable; GBM
544 showed a substantially more uniform
response (Figure 3C).
We observed considerable differences in
the cell speed across the spectrum of 14 pa-
tient-derived samples, both in the presence
and in the absence of PDGF (Figure 3D).Recognizing these patient-specific differences, we analyzed
the distinct features of single-cell response based on the criteria
presented in Figures 3A–3C, namely, based on the average pop-
ulation response (group I), persistence of response over timeell Reports 15, 2616–2624, June 21, 2016 2619
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Figure 3. Information on Migration Speed Reveals
Important Differences among Patient Samples in
Response to PDGF
(A) Analyzing the fastest quartile (GBM 499) reveals that the
subpopulations display a significant response to PDGF. In
contrast, for the whole population, there is no significant
response.
(B) Migration speed time lapse demonstrates that sample
GBM501 does not respond to PDGF at all times (compared to
GBM 609); on average, however, both samples respond
significantly to PDGF.
(C) Both GBM 630 andGBM 544 samples display a significant
increase in average migration speed (*p < 0.05, **p < 0.01,
***p < 0.001, Wilcoxon rank-sum test). However, GBM 630
has a significantly larger number of fast outliers, while GBM
544 displays a uniform increase in speed.
(D) The platform allows patient sample classification based on
multiple characteristics, permitting a better description of the
heterogeneity of the samples. We compare 14 patients’ GBM
cell lines. The samples were grouped based on whether there
is a significant increase (p < 0.05, Wilcoxon rank-sum test) in
average migration speed in response to PDGF (group I) and
whether this significant increase is persistent over time
(group II). Furthermore, samples are grouped based on the
number of outliers (cells faster than the fastest cells in the
control group) with a threshold of 4 cells (5%, for a total of 80
cells) (group III). For reference, the PDGFRa protein expres-
sion level (group IV) and the subclass of the GBM cells
(group V) are also provided.
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(group II), and presence of outliers (group III) (Figure 3D). For
each of these criteria, we identified PDGF-responsive and
PDGF-unresponsive groups. There was overlap among strongly
PDGF-responsive groups in all groups, which we thus treated as
the consensus PDGF-responsive samples (marked in Figure 3D).
However, several patient samples (GBM 544, GBM 549, and
GBM501) were PDGF responsive by some criteria. To determine
whether PDGFRa expression level could serve as a molecular
marker predictive of enhanced PDGF responsiveness, we as-
sayed the tumor samples for expression of this receptor.
Although all consensus PDGF-responsive samples had high
expression of PDGFRa (Figures 2A, 2B, S3B, and S3C), similarly
high levels of the receptor were found in several samples in the
consensus PDGF-unresponsive group (GBM 626, GBM 612,
and GBM 854). The failure of these samples to respond in migra-
tion experiments may be due to differences in downstream ef-
fectors of PDGFRa, stressing the difficulty of using molecular
markers alone in the classification of the aggressive migration
phenotype, as is evident from clinical data showing no correla-
tion between PDGFRa expression and survival (Figure 2J). Dif-
ferential expression of PDGFRa across the groups might also
relate to the subtype of the patient tumors. A subclassification
study of our GBM samples only yielded two subtypes: mesen-
chymal and proneural. Previous studies have observed higher
amplification and mutation rates of the PDGFRA gene in the pro-
neural subtype of GBM (Verhaak et al., 2010).We did not observe
a clear correlation between expression of this gene and tumor
subclass. High levels of PDGF-triggered cell migration can be
achieved in various ways, and they may not be revealed by a
simple molecular signature. However, the aggressive migration
phenotype can be translated into enhanced invasiveness. These
results highlight potential advantages of our single-cell pheno-
type analysis.
Migratory Behavior Correlates with Clinical Tumor
Characteristics
The degree of cell migration may reflect the propensity for inva-
sive tumor spread. We examined more than 35 factors related to
each patient’s tumor, general health, and demographics (Table
S1). We found that the migratory response of GBM samples to
PDGF correlated with time to tumor recurrence after surgical
resection (Figures 4A and 4B). This correlation was particularly
significant when the analysis was focused on the consensus-
responsive and consensus-unresponsive groups (Figure 4A). In
comparisons to the whole-cell populations, correlations were
more significant for the aggressively moving cells: either the fast-
est 25%of the cells or the outlier population (Figure 4B). We con-
trasted several characteristic tumor features visualized in the
MRI of the patients with the responsiveness to PDGF (Figures
4C and 4D). Tumors from the consensus PDGF-responsive sub-
set (Figure 4D) were larger and more spread out than those from
the PDGF-unresponsive subset. We observed statistically signif-
icant differences in the anatomical location of the tumors; all
consensus PDGF-responsive samples were in the frontal lobe
(Figure 4E), but temporal lobe tumor samples commonly fell
into the PDGF-unresponsive subgroup. Migration analysis of
GBM cells revealed that higher directionality (i.e., alignment of
the migration to the patterns) correlated with longer recurrencetimes (univariate Cox analysis, p = 0.002) (Figures 4F and S4A).
Because alignment of the migration is associated with the
strength of cell-substrate adhesion (Kim et al., 2009a; Garzon-
Muvdi et al., 2012), this result may reflect a higher propensity
in more aligned cells to adhere to ECM, leading to retarded
migratory response and delayed tumor spread. Blind, qualitative
analysis of patient tumor samples by a neuropathologist re-
vealed that the cells were small and that the tumors yielding
PDGF-responsive samples had marked microvascular prolifera-
tion. The latter feature is commonly associated with advanced
progression, receptor tyrosine kinase amplification, and worse
prognosis (Louis, 2006; Fomchenko and Holland, 2007).
PDGF-responsive samples emerged from tumors that resulted
in shorter recurrence times, after controlling for factors known
to be associated with recurrence (age, Karnofsky Performance
Scale score, extent of resection, and adjuvant therapy)
(p = 0.0009) (Table S1). However, survival times showed a less
significant correlation to PDGF responsiveness with the limited
number of patient samples tested (Figure S4B).
We supplemented these findings with comparisons to more
traditional protein expression analyses. First, we segregated
the tumor sample into groups based on PDGFRa expression,
which revealed trends in patient tumor characteristics that
were supportive of our migration analysis (Figure 3D). However,
grouping the samples according to PDGFRa expression or mo-
lecular subclassification did not yield significant differences
in predicting time to recurrence (Figures S4C and S4D). More-
over, the difference in tumor location between high- and low-
expression groups was not statistically significant. Second, we
mined the public Rembrandt database of glioblastoma patients
to investigate the relationship between tumor location and
PDGFRa expression. Examination of 47 patients revealed no sig-
nificant relationship between the two characteristics (Figures
S4E and S4F). Taken together, these findings suggest that
RNA expression is a weaker predictor of patient outcomes
than is our phenotypic migration analysis.
DISCUSSION
The heterogeneity and invasive nature of glioblastoma and other
aggressive cancers highlights the importance of assaying cell
migration as a phenotypic feature predictive of clinical out-
comes. Here we describe a simple but information-rich experi-
mental platform aimed at the analysis of primary patient samples
on a single-cell level. This platform allows high-throughput
screening of the effects of variable extracellular milieu. Using
this method on a range of patient-derived samples and contrast-
ing the results of the analysis with respective clinical information
revealed substantial predictive power, particularly when cell
migration was examined in conjunction with the effects of
PDGF. This result strongly suggests that cell migration, as exam-
ined in structured, mechanically defined culture conditions, can
be predictive of more complex in vivo invasion processes and
can be a powerful phenotypic analysis tool with strong clinical
implications. Prior attempts to examine glioma cell migration
and its relationship to tumor progression (Friedlander et al.,
1996) have used 2D surfaces and have not achieved such direct
predictions of patient-specific tumor features as we have in theCell Reports 15, 2616–2624, June 21, 2016 2621
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Figure 4. GBM Migratory Response to PDGF Correlates with Patient Tumor Characteristics
(A andB) Kaplan-Meier plots comparing recurrence betweenPDGF-responsive and PDGF-unresponsive groups (n = 11 patient tumors, consensus group) (A) and
based on the criteria in Figure 3D (n = 14 patient tumors, weak and strong responders) (B). The p values were calculated using a two-tailed log-rank (Mantel-
Cox) test.
(C and D) MRI scans of patients with tumors from the unresponsive group (C) and the responsive group (D).
(E) Distribution of PDGF-responsive and PDGF-unresponsive tumors that formed in specific locations in the brain (n = 11 patient tumors, Barnard’s exact test).
(F) Time to recurrence for GBM samples separated into low-directionality (<3.25) and high-directionality (R3.25) groups (nR 4, mean + SEM,Wilcoxon rank-sum
test) (the threshold of 3.25 was determined using linear discriminant analysis).present work. This emphasizes the benefits of analyzing hetero-
geneities within samples and using surfaces that better mimic
in vivo conditions.
The significant correlation of migratory behavior with time to
recurrence and tumor location provides crucial insight into this
disease. Recurrence of glioblastoma after tumor resection is
the primary cause of death in patients and is one of the most
important predictors of future patient outcomes (Chaichana
et al., 2013, 2014). This study provides a simple method to glean
information about these phenomena. Our finding that most
PDGF-unresponsive tumors are derived from the temporal lobe
could suggest that PDGF signaling is less critical to tumor pro-
gression in this region of the brain. Direct access to individual2622 Cell Reports 15, 2616–2624, June 21, 2016cell migration analysis can be important for future treatment mo-
dalities. Our experimental platform has important advantages
over 2Dmigration assays, because it provides a cellular environ-
ment similar to in vivo conditions (as evidenced in the similarity of
several aspects of migration in ex vivo human brain tissue and a
3D hydrogel, e.g., increased cell polarity and migration speed).
Previous studies have highlighted the importance of these fac-
tors in migration (Friedl and Wolf, 2010; Petrie et al., 2009; Kim
et al., 2012; Beadle et al., 2008; Louis, 2006). Another advantage
is the reduced number of cells required when compared to
commonly used transwell migration assays. Furthermore, trans-
well assays fail to yield the information on migration and
morphology of individual cells and only originate endpoint
information (Kim et al., 2009a). We found a substantial degree of
heterogeneity in the glioblastoma samples analyzed. The
increased average migration speed of a cell population in the
presence of PDGF was ascribed to a small subpopulation of
aggressive cells (approximately 25%). Knowledge of the degree
of population heterogeneity can be critical to the decision-mak-
ing in the clinic (Snuderl et al., 2011; Szerlip et al., 2012). In addi-
tion, our tissue mimetic platform can distinguish the effects of
cell proliferation and migration phenotypes, which can be a con-
founding factor in both transwell and in vivo migration studies.
Our results also highlight advantages of the proposed
method over traditional protein expression assays. We observed
an incomplete correlation between receptor expression and
response to PDGF signaling, possibly due to veiled differences
in the signal transduction pathways. We demonstrated that pro-
tein expression analysis was less sensitive and less robust at
predicting differences among patient tumor features. Genomic
and proteomic approaches also suffer from limited supplies of
primary tissues available for their cumbersome requirements of
cellular material.
Overall, the results here support the proposed methodology
as a simpler, more biomimetic, and informative method to gain
critical information about patient tumors and cell populations.
The analysis presented here reveals the importance of careful
engineering of chemical and mechanical extracellular milieu in
cell migration analysis. We believe that this methodology will
provide an important prognostic tool, with benefits that include
high-throughput, label-free analysis of single-cell resolution;
low demand for precious primary cell samples; and better phys-
iological relevance compared to other migration assays.
EXPERIMENTAL PROCEDURES
Cells
Human tissues were obtained at Johns Hopkins medical institutions and used
with approval of the Institutional Review Board. Glioblastoma pathologically
confirmed tumor samples (GBM 221, GBM 253, GBM 276, GBM 318, GBM
499, GBM 501, GBM 544, GBM 549, GBM 567, GBM 609, GBM 612, GBM
626, GBM 630, and GBM 854) were derived from primary intraoperative tis-
sues of patients undergoing surgery. Tissue donors received no treatment
before surgery.
Construction of a Multi-well Nanopatterned Device
The topographic nanopatterned substratum, consisting of parallel ridges
350 nm wide and 500 nm high that are spaced 1.5 mm apart, was fabricated
onto glass coverslips as previously described (Kim et al., 2009a, 2009b) using
UV-assisted capillary molding techniques.
Time-Lapse Microscopy of Live Cells and Quantitative Analysis of
Cell Morphology and Migration
Cell migration was observed using time-lapsemicroscopy (Movies S1, S2, and
S3). To enable long-term observation, the multi-well, nanopatterned device
was mounted on the stage of a motorized inverted microscope (Olympus
IX81) equipped with a Photometrics hCascade 512B II charge-coupled device
camera and temperature- and gas-controlling environmental chamber. Phase-
contrast cell images were automatically recorded under a 103 objective
(numerical aperture = 0.30) using SlideBook 4.1 software (Intelligent Imaging
Innovations) for 10–15 hr at 10 or 20 min intervals. Because cell-cell contact
is known to affect the extent of cell spreading and migration, cells were plated
at low density (4 3 104 cells ml1) to allow isolated movements. A custom-
made MATLAB script was used to allow manual tracking and measurement
of cells frame by frame.Tumor Xenografts
Animal protocols were approved by the Johns Hopkins School of Medicine
Animal Care and Use Committee. For intracranial xenografts, severe com-
bined immunodeficiency mice received 100,000 viable cells in 1 ml of
DMEM/F12 serum media without growth factors by stereotactic injection
into the right striatum. Cells were cultured in DMEM/F12 serum media with
epidermal growth factor, fibroblast growth factor, and PDGF ligand for 3weeks
before injections were performed. Cell viability was determined by trypan blue
dye exclusion. Mice were perfusedwith 4%paraformaldehyde at the indicated
times, and the brains were removed for histological analysis.
Statistical Analysis
Results are presented as mean + SEM. The Mann-Whitney rank-sum test was
for pairwise comparisons; Dunn’s test (rank-based ANOVA) was used in mul-
tiple group comparisons.When noted, Student’s t test or standard ANOVA (the
Holm-Sidak method) was used. Univariate Cox analysis was used to identify
correlations among tumor characteristics. To group data, thresholds were
determined using linear discriminant analysis as previously described (Lin
et al., 2012). Statistics were analyzed using Sigmaplot, GraphPad Prism,
and MATLAB software.SUPPLEMENTAL INFORMATION
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